Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0OYUQB)
| ADC Name |
DB-2304
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
DB-2304
Click to Show/Hide
|
|||||
| Organization |
Duality Biotherapeutics (DualityBio) (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Hu033-03
|
Antibody Info | ||||
| Antigen Name |
C-type lectin domain family 4 member C (CLEC4C)
|
Antigen Info | ||||
| Payload Name |
P2025
|
Payload Info | ||||
| Payload Target |
Glucocorticoid receptor (NR3C1)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion for Part A: healthy volunteers aged 18-55; BMI-compliant; normal medical history/physical exams/lab tests/ECG; commitment to effective contraception and protocol compliance.
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06625671 | Clinical Status | PHASE1 | ||
| Clinical Description | A Randomized, Double-Blind, Placebo- and Positive-Controlled, Single Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DB-2304 Injection in Healthy Adult Participants | ||||
| Primary Endpoint |
Primary safety endpoints include TEAEs and SAEs (monitored up to 112 days for Part A/196 days for Part B post-treatment), ECG parameters (HR/PR/QT/QTcF intervals), and vital sign measurements (weight, heart rate, pulse, respiratory rate, body temperature) with baseline change analysis.
|
||||